Literature DB >> 334117

Mutagenicity studies with praziquantel, a new anthelmintic drug: tissue-, host-, and urine-mediated mutagenicity assays.

J Obermeier, H Frohberg.   

Abstract

Praziquantel, a new anthelmintic drug with activity against all species of schistosomes pathogenic to man, and against a wide range of Cestodes, was tested for mutagenic potential. For the detection of both base substitutions and frameshift mutations, Salmonella typhimurium TA 100 and TA 98 were used as tester strains. Using the plate assay with and without added S-9, host-mediated assay and urine-mediated assay without and after incubation with beta-glucuronidase/arylsulfatase, no mutagenic activity could be detected.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334117     DOI: 10.1007/bf00293649

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  17 in total

1.  Acetylornithinase of Escherichia coli: partial purification and some properties.

Authors:  H J VOGEL; D M BONNER
Journal:  J Biol Chem       Date:  1956-01       Impact factor: 5.157

2.  Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids.

Authors:  J McCann; N E Spingarn; J Kobori; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

3.  Hycanthone-induced hepatic changes in mice infected with Schistosoma mansoni.

Authors:  W H Haese; D L Smith; E Bueding
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

4.  Mutagenic activity of cyclophosphamide, ifosfamide, and trofosfamide in different genes of escherichia coli and salmonella typhimurium after biotransformation through extracts of rodent liver.

Authors:  J Ellenberger; G Mohn
Journal:  Arch Toxicol       Date:  1975       Impact factor: 5.153

5.  Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity.

Authors:  H R Glatt; F Oesch; A Frigerio; S Garattini
Journal:  Int J Cancer       Date:  1975-11-15       Impact factor: 7.396

6.  Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test.

Authors:  B N Ames; J Mccann; E Yamasaki
Journal:  Mutat Res       Date:  1975-12       Impact factor: 2.433

7.  Carcinogenic effects of niridazole.

Authors:  H K Urman; O Bulay; D B Clayson; P Shubik
Journal:  Cancer Lett       Date:  1975-11       Impact factor: 8.679

8.  A simple method for the detection of mutagens in urine: studies with the carcinogen 2-acetylaminofluorene.

Authors:  W E Durston; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

9.  Mutagen testing using TRP+ reversion in Escherichia coli.

Authors:  M H Green; W J Muriel
Journal:  Mutat Res       Date:  1976-02       Impact factor: 2.433

10.  Praziquantel, a new board-spectrum antischistosomal agent.

Authors:  R Gönnert; P Andrews
Journal:  Z Parasitenkd       Date:  1977-07-21
View more
  5 in total

1.  Multicentre trials of praziquantel in human schistosomiasis: design and techniques.

Authors:  A Davis; D H Wegner
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

2.  Comparison of the Ames assay and the induction of sister chromatid exchanges: results with ten pharmaceuticals and five selected agents.

Authors:  E K Shubber; D Jacobson-Kram; J R Williams
Journal:  Cell Biol Toxicol       Date:  1986-09       Impact factor: 6.691

3.  Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems.

Authors:  L Machemer; D Lorke
Journal:  Arch Toxicol       Date:  1978-01-25       Impact factor: 5.153

Review 4.  A Novel Strategy to Predict Carcinogenicity of Antiparasitics Based on a Combination of DNA Lesions and Bacterial Mutagenicity Tests.

Authors:  Qianying Liu; Zhixin Lei; Feng Zhu; Awais Ihsan; Xu Wang; Zonghui Yuan
Journal:  Front Public Health       Date:  2017-11-09

5.  Promotion of rat hepatocarcinogenesis by praziquantel.

Authors:  T Shirai; K D Joong; K Hakoi; W Thamavit; C Pairojkul; T Hoshiya; R Hasegawa; N Ito
Journal:  Jpn J Cancer Res       Date:  1991-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.